HTFL | Ticker Profile - Titan Protect

HTFL

Heartflow, Inc.

Healthcare · Health Information Services · NMS

$28.10

Data: 2026-05-15

✓ ETHICAL PASS

MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-101.04

Based on estimated future earnings — lower means cheaper

Rev Growth

+40.5%

Year-over-year revenue change

Profit Margin

-66.3%

How much profit the company keeps from each dollar of revenue

ROE

-111.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$37.67

+34% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 6 analysts covering this stock

About Heartflow, Inc.

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in Mountain View, California.

https://www.heartflow.com

Country: United States Employees: 843 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.8% PASS

Debt must be below 33% of total assets

Cash Ratio

6.4% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.294

Positive but modest risk-adjusted returns

Kelly Fraction

0.0141

Marginal edge — very small allocation suggested

Calmar Ratio

-0.137

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-6.7%

Historical annualised return based on price data

Max Drawdown

-48.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$41.22

32% below the year high

52W Low

$20.13

40% above the year low

Avg Volume

1,324,967

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.3%

Moderate short interest

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.07

Conservative use of debt — low financial risk

Current Ratio

5.20

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.87

Like current ratio but excludes inventory — stricter test

Gross Margin

76.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-36.1%

Profit from core operations before interest and tax

Free Cash Flow

$-30,882,376

Negative — the business is spending more than it generates

Revenue (TTM)

$176M

Total revenue over the last 12 months

Net Income

$-116,791,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$43.00

Target Median

$37.67

Target Low

$35.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-05-18	ROGERS CAMPBELL D M.D.	Officer	9,219	$261,266
2026-05-18	ROGERS CAMPBELL D M.D.	Officer	9,219	$175,161
2026-05-11	FARQUHAR JOHN C. M.	Chief Executive Officer	22,562	$657,005
2026-04-30	BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C.	Beneficial Owner of more than 10% of a Class of Security	2,000,000	$58,898,336
2026-04-10	FARQUHAR JOHN C. M.	Chief Executive Officer	22,562	$602,857
2026-04-01	ROGERS CAMPBELL D M.D.	Officer	64,533	$1,590,093
2026-04-01	ROGERS CAMPBELL D M.D.	Officer	67,017	$150,556
2026-03-19	ROGERS CAMPBELL D M.D.	Officer	64,533	$1,658,033
2026-03-19	ROGERS CAMPBELL D M.D.	Officer	67,017	$148,778
2026-03-18	FARQUHAR JOHN C. M.	Chief Executive Officer	9,725	$243,125

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go